CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA

25-27 February 2015 | Boston, USA

Tel: +1 212 531 5898 | Email: [email protected]

RESEARCHED & DEVELOPED BY:

Unlocking Precision Genome Editing for Therapeutic Development & Biomedical Research Applications

GEORGE CHURCHHarvard University

ALEXANDRA GLUCKSMANN Editas Medicine

ERIC RHODESHorizon Discovery

KEITH JOUNG Harvard University

RODGER NOVAKCRISPR Therapeutics

This is designed to describe the profound impact CRISPR is having on basic research and therapeutic development. It will explore the research tools, bioinformatics and expertise needed to make the most of this breakthrough technology

Eric Rhodes onCRISPR Congress 2015

crispr-congress.com

LEAD PARTNER PROGRAM PARTNERS EXHIBITORHOSTING PARTNER

1 6

3 8

2 7

4 9

5 10

BENEFITS OF ATTENDING

Tel: +1 212 531 5898 Email: [email protected]

crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing

CRISPR Precision Gene Editing Congress Boston, USA | 25-27 February 2015

Enhance the Implementation of CRISPR Gene Editing Technology & Advance your Research

Seize the value of CRISPR/Cas9 gene editing and discover its evolving application in target identification and therapeutic development

With its ground breaking convenience and simplicity, the emergence of CRISPR genome technology has taken gene editing from a niche pursuit and opened it up to the wider scientific community, in turn revolutionizing and optimizing the application of highly precise genome editing.

Key industry leaders will gather at the inaugural CRISPR Precision Gene Editing Congress with an ultimate purpose of addressing the importance of overcoming specificity, efficiency and delivery challenges associated

with the CRISPR/Cas9 system. Furthermore, pioneers will showcase the exploding biomedical and therapeutic potential of gene editing tools for drug discovery and development.

CRISPR congress brings together those who are striving to unlock the potential and capture the innovative applications of CRISPR technology under one roof.

Utilize the industry’s greatest minds to optimize your gene engineering applications.

Discover the approaches being applied to overcome CRISPR/Cas9 off-cuts and enhance specificity

Harness the bioinformatic approach to detect off-cuts and improve CRISPR/Cas9 specificity

TOP 10 REASONS TO ATTEND CRISPR CONGRESS

Harness the innovative approaches being utilized to overcome in vivo delivery challenges in the development of disease models

Explore how CRISPR based functional genomic screening is being applied to improve identification and validation of new drug targets

Explore how CRISPR technology is being utilized in basic research to enhance your own application of CRISPR gene editing

Discover how CRISPR technology is being applied to compliment other gene editing tools

Learn about the application of CRISPR technology in epigenome editing of human cells and stem cell biology

Harness the high throughout methods being developed for efficient RNA delivery and gene editing

Enhance your knowledge on key safety issues surrounding the development of CRISPR-based therapeutics

Learn about the platform advancements required to advance CRISPR technology to the clinic and develop CRISPR-based therapies

SPEAKER FACULTY




Eric RhodesChief Technology OfficerHorizon Discovery

Katrine BosleyChief Executive Officer Editas Medicine

Keith JoungAssociate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

Alexandra GlucksmannChief Operating OfficerEditas Medicine

Matthew PorteusAssociate Professor of PaediatricsStanford University

Charles GersbachAssistant Professor, Biomedical Engineering, Investigator, Center for Genomic and Computational Biology

Duke University

Daniel AndersonSam Goldblith Associate ProfessorMassachusetts Institute of Technology (MIT)

David BumcrotSenior Director, Molecular and Cell BiologyEditas Medicine

Mark KayProfessor of Pediatrics and GeneticsStanford University

Yi Yang Senior Research InvestigatorNovartis

Kiran MusunuruAssistant Professor, Stem Cell and Regenerative BiologyHarvard University

Stanley QiAssistant Professor, Bioengineering and Chemical and Systems BiologyStanford University

Gregory DavisR&D Manager, Molecular BiotechnologySigma-Aldrich Corporation

Jason PotterSenior Scientist in Protein EngineeringThermo Fisher Scientific

TJ CradickDirector of Protein Engineering FacilityGeorgia Institute of Technology

David LiuProfessor of Chemistry and Chemical Biology, Howard Hughes Medical Institute InvestigatorHarvard University

Wenning QinAssociate Director of Genetic Engineering TechnologiesThe Jackson Laboratory

Richard ChenPrincipal Scientist, Genetics and PharmacogenomicsMerck

Rodger NovakChief Executive OfficerCRISPR Therapeutics

Terence FlotteProfessor, Deanand Provost, University of Massachusetts Medical School

Derrick RossiAssistant Professor, Stem Cell and Regenerative BiologyHarvard University

Christian MuellerAssistant Professor, PaediatricsUniversity of Massachusetts Medical School

John FederAssociate Director of Genome BiologyBristol-Myers Squibb

Hari JayaramSenior ScientistEditas Medicine

Jochen WelckerSenior Manager Scientific DevelopmentTaconic Biosciences GmbH

Vittorio SebastianoAssistant Professor of Obstetrics and Gynecology, Director of Human Pluripotent Stem Cells Core Facility and TKTCStanford Cancer Institute

George ChurchProfessor of GeneticsHarvard Medical School

CONFERENCE DAY ONE

8.00 Registration, Breakfast & Networking

9.00 Welcome Address from Lead Partner Horizon Discovery Eric Rhodes, Chief Technology Officer, Horizon Discovery

9.05 Chair’s Opening Remarks Alexandra Glucksmann, Chief Operating Officer, Editas Medicine

9.10 Unlocking Future CRISPR Applications: Conversations That Matter Gain an exclusive insight into the latest developments within the field of CRISPR technology via one-on-one interviews with a panel of key opinion leaders. Join those paving the way in implementing CRISPR technology for therapeutic and biomedical applications, as well as in drug discovery and development. The panel will discuss and answer the following questions:

• Are we in a CRISPR revolution?

• What has been the impact so far and how high can CRISPR reach?

• How can we make this technology better and work harder?

• What are the potential applications of CRISPR in drug discovery and development?

• How is the technology being utilized for gene therapy?

Moderator: Alexandra Glucksmann, Chief Operating Officer, Editas Medicine

Keith Joung, Associate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

Rodger Novak, Chief Executive Officer, CRISPR Therapeutics

Charles Gersbach, Assistant Professor, Department of Biomedical Engineering, Investigator, Center for Genomic and Computational Biology, Co-Director, Center for Biomolecular and Tissue Engineering, Duke University

Katrine Bosley, Chief Executive Officer, Editas Medicine

10.00 CRISPR and the Rapidly Changing Landscape of Genome Editing• Learnings accumulated from over 1 year of industrial application of CRISPR to

in vitro and in vivo genome editing. Incorporation of CRISPR into products, services and research programs that enable customers engaged at every stage of the healthcare continuum

• Harnessing gene editing of haplogenic cell lines

• A bioinformatics approach for CRISPR experimental design

Eric Rhodes, Chief Technology Officer, Horizon Discovery

Horizon welcome’s their partners:Tilmann Burckstummer, Director Research and Development, Horizon Genomics GmbH

Riley Doyle, Chief Executive Officer, Desktop Genetics Ltd

10.30 Morning Refreshments & Speed Networking

Harnessing CRISPR Technology for Epigenome Editing

11.30 Optimizing Technologies for CRISPR-Based Targeted Genome and Epigenome Editing of Human Cells• Harness the latest advances in the technologies for highly efficient CRISPR-based

genome editing of human cells

• Learn about the innovative approaches in CRISPR-mediated epigenome editing of human cells

Keith Joung, Associate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

12.30 Genome and Epigenome Modification with ZFNs and CRISPR/Cas Systems• CRISPR nuclease and highly specific paired nickase formats for genome editing in

animal and plant cells

• Donor DNA formats and their impact on DNA repair rates

• New experimental possibilities using lentiviral delivery of CRISPR elements and CRISPR-based screening

• Zinc finger and CRISPR-mediated epigenetic modifications

Gregory Davis, R&D Manager, Molecular Biotechnology, Sigma-Aldrich Corporation

1.00 Networking Lunch & Speakers’ Corner

2.00 Epigenome Editing and Controlling Cell Phenotype• Utilizing CRISPR/Cas9-based epigenome editors which are exceptionally specific with

regards to genome-wide DNA-binding, gene regulation, and chromatin remodeling

• Discover how gene network activation by CRISPR/Cas9-based epigenome editors can be used to reprogram cell phenotype and drive pluripotent cell differentiation

• Harness these enhanced strategies for disease modeling, drug screening and potentially regenerative medicine

Charles Gersbach, Assistant Professor, Department of Biomedical Engineering, Investigator, Center for Genomic and Computational Biology, Co-Director, Center for Biomolecular and Tissue Engineering, Duke University




Wednesday 25th February 2015 Keynote Session Interactive Session Networking Session

The Discovery & Implementation of CRISPR Technology in Innovative Applications

2.30 Genome Editing Tools and Workflows to Address Cell Engineering Needs • Utilising the Cas9 protein or cas9 mRNA

• Cationic lipid mediated transfection or electroporation workflows

• Developing up to 95% single knock outs in difficult cell lines

• High efficiencies for bi-allelic multiplex knock out

Jason Potter, Senior Scientist in Protein Engineering, Thermo Fisher Scientific

3.00 Genome Editing to Dissect the Role of Retroviral lnCRNAs in Human Development• Overview of lncRNAs of retroviral origin in human and primates

• Role of lncRNAs in human pluripotent cells

• Genome editing in diverse embryonic cell types and functional characterization on one specific lncRNA

Vittorio Sebastiano, Assistant Professor of Obstetrics and Gynecology, Director of Human Pluripotent Stem Cells Core Facility and Transgenic, Knockout and Tumor Model Center (TKTC), Stanford Cancer Institute

3.30 Ultra-Sensitive Quantification of Genome Editing Events by Droplet Digital PCR• Genome editing events are rare, with NHEJ and HDR allele frequencies often <5%

in targeted cell populations

• Locus-specific quantification of NHEJ versus HDR alleles is emerging as an important readout for optimizing genome-editing protocols

• Here we describe the use of droplet digital PCR (ddPCR) for ultra-sensitive absolute quantification of NHEJ and HDR alleles in edited samples

Jennifer Berman , Staff Scientist, Applications, Digital Biology Center, Bio-Rad Laboratories

4.00 Afternoon Refreshments & Poster Session

4.30 Technologies and Applications Enabled by CRISPR-Mediated Gene Regulation • Establishing technologies for targeted gene regulation using a nuclease deficient

CRISPR system

• Development of CRISPR technology for different goals of gene regulation such as activation or repression, known as CRISPR interference (CRISPRi) or CRISPR activation (CRISPRa)

• Applications of CRISPRi/a for drug target characterization, cell engineering, and genome-wide screenings

Stanley Qi, Assistant Professor, Bioengineering and Chemical and Systems Biology, Stanford University

5.00 Interactive CRISPR MastermindThe CRISPR speaker faculty is second to none but there is just as much knowledge in the audience as there is onstage. Tap into the wealth of perspectives on key issues during interactive discussions, specifically designed so you can learn from fellow peers and CRISPR experts. Drive your own learning, crowd-source ideas and get inspired!

1. What are the current approaches being utilized for enhancing CRISPR specificity - overcoming off-target challenges?

2. How to overcome delivery challenges within genome editing

3. Utilizing CRISPR technology for modeling disease: How CRISPR technology can be best applied to convert human GWAS/whole genome sequencing data from “association” to “causation”?

4. How to use a bioinformatic approach for enhancing CRISPR applications

5. What challenges need to be addressed to establish safety models for gene therapy?

MODERATED BY: Keith Joung, Associate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

David Liu, Professor of Chemistry and Chemical Biology, Howard Hughes Medical Institute Investigator, Harvard University

David Bumcrot, Senior Director, Molecular and Cell Biology, Editas Medicine

Richard Chen, Principal Scientist, Genetics and Pharmacogenomics, Merck

Matthew Porteus, Associate Professor of Paediatrics, Stanford University

John Feder, Associate Director of Genome Biology, Bristol-Myers Squibb

5.50 Chair’s Closing Remarks Alexandra Glucksmann, Chief Operating Officer, Editas Medicine

6.00 Close of Day 1

6.10 Evening Drinks Reception Hosted by Horizon Discovery




Keynote Session Interactive Session Networking Session

CONFERENCE DAY ONE - CONTINUEDWednesday 25th February 2015




CONFERENCE DAY TWO

8.00 Breakfast & Networking

9.00 Chair’s Opening RemarksCRISPR State of Address- What can we take forward from the discussions so far?


Overcoming the Main CRISPR Technology Hurdles: Specificity & Delivery

9.10 Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing • To discuss the high throughput methods for developing and characterizing RNA

delivery and gene editing systems

• Developing delivery formulations with in vivo efficacy, and show potential therapeutic application for the treatment of genetic disease, viral infection, and cancer

Daniel Anderson, Sam Goldblith Associate Professor, Massachusetts Institute of Technology (MIT)

9.40 Bioinformatics for Testing and Improving CRISPR Specificity• Harnessing bioinformatics for the determination of possible off-target cleavage

sites

• Developing assays for off-target cleavage events

TJ Cradick, Director of Protein Engineering Facility, Georgia Institute of Technology

10.10 From “Gene Editing” to True Genome-Scale Engineering”• Reducing issues with competing events like Non-Homologous End-Joining

(NHEJ) and efficiency of large construct insertion/replacements in homologous recombination editing

• Overcoming NHEJ events with the use of a promising alternative to double-strand breaks (CRISPR, dual nickase or FokI) via recombinase/integrase mechanisms

George Church, Professor of Genetics, Harvard Medical School

10.40 Morning Refreshments & Networking

11.00 Increasing the Therapeutic Relevance of CRISPR Technologies to Address Delivery and Specificity Challenges• Discover the successful engineering of TALEN and Cas9 variants with greatly

improved specificity

• Harness a new approach to the delivery of proteins that has enabled the highly potent, non-endosomal delivery of genome-editing proteins into mammalian cells

David Liu, Professor of Chemistry and Chemical Biology, Howard Hughes Medical Institute Investigator, Harvard University

12.00 Bioinformatic Approaches to Optimize Guide-RNA Design and Assay Cas9 Specificity• Explore the various algorithms and tools to assist in design of guide-RNAs for

Cas9 mediated gene editing

• Explore formats to standardize reporting of CRISPR mediated gene editing experiments

Hari Jayaram, Senior Scientist, Editas Medicine

12.30 Networking Lunch

Application of CRISPR in Disease Modeling & Drug Screening

1.30 Interrogation of Novel Genes and Loci in Cardiovascular Diseases with CRISPR Genome Editing • Utilizing CRISPR to interrogate novel genes identified by genomic studies of

cardiovascular disease

• Implementing CRISPR to generate reporter cell lines for functional and drug screens

Kiran Musunuru, Assistant Professor, Stem Cell and Regenerative Biology, Harvard University

2.00 CRISPR/Cas-Mediated Genome Engineering in Mice with High Efficiency and Throughput• Significantly improving the efficiency of CRISPR/Cas-mediated insertion of a

transgene into an endogenous locus through pronuclear injection into zygotes

• Using whole genome sequencing to comprehensively characterized the off-target effect of CRISPR/Cas9 targeting the Nanog locus

Wenning Qin, Associate Director of Genetic Engineering Technologies, The Jackson Laboratory

Thursday 26th February 2015 Keynote Session Interactive Session Networking Session




2.30 Therapeutic Genome Editing in Human Hematopoietic Stem Cells using CRISPR/Cas9 Technology• Harnessing CRISPR/Cas9 technology for applying genome editing in human

hematopoietic stem cells

• How the CRISPR/Cas9 system can be used to achieve very high on-target and very low off-target mutagenesis in human CD34+ human hematopoietic stem cells

Derrick Rossi, Assistant Professor, Stem Cell and Regenerative Biology, Harvard University

3.00 Rapid Generation of Mouse and Rat Mutants by CRISPR/Cas in One-Cell Embryos• Experiences from the implementation of CRISPR/Cas-technology to routine model

generation

• Generation of knock-in- and conditional knock-out alleles

• Tailoring and refining existing humanized mouse models

Jochen Welcker, Senior Manager Scientific Development, Taconic Biosciences

3.30 A CRISPR Way for Drug Discovery• Harnessing CRISPR technology for target validation and for identifying target of

compound

Yi Yang, Senior Research Investigator, Novartis

4.00 Afternoon Refreshments

Advances in Genome Editing Technologies for Precision Gene Therapy

4.30 Developing a Combination of Genome Editing Technologies to Enhance Application Specific Genetic Engineering• Understand the advantages and disadvantages of the different nuclease platforms

that are currently available and what criteria one might use to choose

• Opportunities and challenges present in translating genome editing to future therapeutics

Matthew Porteus, Associate Professor of Paediatrics, Stanford University

5.00 Alpha-1 Antitrypsin Deficiency Liver Disease: Genome Editing for Animal Models and Gene Therapy• Summary of animal model creation and potential selective advantage of correction

of AAT liver disease

• In vivo proof if concept for gene transfer, gene silencing and genome editing in AAT liver disease

Using Genome Editing to Create a Knockout Mouse for Alpha-1 anti Trypsin and Modify Hepatocytes for Stem Cell Therapy• Methods developed for knocking out 5 tandem repeats of the serpina1 gene in

mice

• Editing hepatocytes to increase their secretion of alpha 1 antitrypsin

Terence Flotte, Professor, Dean and Provost, University of Massachusetts Medical School

Christian Mueller, Assistant Professor, Paediatrics, University of Massachusetts Medical School

5.30 Therapeutic Promoterless Gene Targeting Without Nucleases • Provide a general understanding of rAAV-based gene therapeutics including

current successes and limitations in a clinical setting

• Discuss the proof-of-concept studies to support therapeutic application of promoter less genome editing using rAAV vectors

Mark Kay, Professor of Pediatrics and Genetic, Stanford University

6.00 Concluding Objectives for CRISPR Community – What’s on the Horizon?


6.05 Close of Congress

6.10 Evening Drinks Reception Hosted by Sigma-Aldrich

CONFERENCE DAY TWO - CONTINUEDThursday 26th February 2015 Keynote Session Interactive Session Networking Session

WORKSHOP A

WORKSHOP B




During this 3 hour interactive workshop, you will learn:

• What indications are addressable by current CRISPR technology?

• What platform advancements are necessary to significantly broaden the range of CRISPR-based therapeutics?

• What are the key safety issues for clinical development of CRISPR technology?

During this 3 hour interactive workshop, you will learn:

• The main challenges surrounding CRISPR specificity

• The latest efforts in the field to define off-target effects of CRISPR-Cas nucleases

• What approaches need to be harnessed to improve CRISPR-Cas nuclease specificities of action in human cells

Dr. David Bumcrot is Senior Director of Molecular & Cell Biology at Editas Medicine, Inc. During his 18 year career he has held positions at a number of innovative biotechnology companies developing novel therapeutic technologies. Prior to Editas, he was a Director of Research at Alnylam Pharmaceuticals where he worked to advance several novel RNAi-based drugs into clinical testing.

Workshop LeaderDavid BumcrotSenior Director, Molecular and Cell BiologyEditas Medicine

Advancing CRISPR Technology into the ClinicDate: Friday 27th February 2015 | Time: 9.00am – 12.00pm

Exploring Innovative Approaches: Defining and Improving the Specificities of CRISPR-Cas NucleasesDate: Friday 27th February 2015 | Time: 1.00pm – 4.00pm

Workshop LeaderKeith JoungAssociate Chief of Pathology for Research and the Jim and Ann Orr MGH Research ScholarMassachusetts General HospitalAssociate Professor of PathologyHarvard University

J. Keith Joung is a leading innovator in the field of genome editing. Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He is a scientific co-founder of Editas Medicine, a company dedicated to the translation of genome editing technologies for therapy of human diseases.

SPONSORS

Sigma-Aldrich

Sigma-Aldrich is proud to offer its newest line of genome editing tools, Sigma CRISPRs, to the global research community. Sigma CRISPRs offer rapid, reliable and reproducible results – everything you need for gene editing experiments. Sigma-Aldrich also offers the CRISPR Core Partnership Program providing scientists and core facilities with world class service and a diverse portfolio of innovative CRISPR reagents, with the support of an industry-leading bioinformatics engine. The Cell Design Studio team at Sigma Aldrich, utilizes CRISPR, ZFN, and shRNA technologies to rapidly and efficiently generate model cell lines to be used in basic research, cell-based assays, target validation and much more.

www.sigmaaldrich.com

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life Sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

www.thermoscientific.com

HOSTING PARTNER

PROGRAM PARTNER

The Jackson Laboratory

The Jackson Laboratory is an independent, nonprofit biomedical research institution and a National Cancer Institute-designated Cancer Center with more than 1,500 employees. Headquartered in Bar Harbor, Maine, it has a facility in Sacramento, Calif., and a new genomic medicine institute in Farmington, Conn. The Laboratory’s mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.

www.jax.org

PROGRAM PARTNER




Horizon Discovery

Horizon Discovery combines long scientific heritage in translational research with GENESIS™, a precision gene editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organisations.

www.horizondiscovery.com

LEAD PARTNER

SPONSORS

Bio-Rad

Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics.

www.bio-rad.com

PROGRAM PARTNER

Transposagen

Transposagen is a worldwide leader in genome engineering technologies and services with applications in therapeutics, research & drug discovery, bioproduction, clinical genetic testing and agriculture. Our products and services include Footprint-Free(tm) Gene Editing, NextGEN(tm) CRISPR, XTN(tm) TALENs, and custom cell lines, stem cells, and animal models. Our unique genome engineering capabilities allow for the creation of nearly any genetic modification in any genome.

www.transposagenbio.com

EXHIBITOR

Taconic

Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative animal models and scientific services that facilitate in vivo studies and advance drug discovery. Our solutions enable investigators to obtain reliable data early in the development cycle - reducing costs, accelerating time-to-market, and creating a strong competitive advantage.

tONCO(TM) allows easy access to a comprehensive portfolio of translational rodent models and services covering every stage of preclinical in vivo oncology research.

www.taconic.com

PROGRAM PARTNER




Code: 5164

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

TERMS & CONDITIONS

VENUE AND ACCOMMODATION:

REGISTER

EVENT PRICES

PRICING & VENUE

INDUSTRY*

Package Standard Prices

GOLD PACKAGE: Conference + 2 Workshops $3797 (save $200)

SILVER PACKAGE:Conference + 1 Workshop $3198 (save $100)

BRONZE PACKAGE: Conference Only

$2599

Workshops (each) $699

ACADEMIC*

Package Standard Prices

GOLD PACKAGE: Conference + 2 Workshops $2397 (save $200)

SILVER PACKAGE: Conference + 1 Workshop $1998 (save $100)

BRONZE PACKAGE: Conference Only

$1599

Workshops (each) $499




Venue: Located on the Cambridge side of the Charles River, the newly renovated Royal Sonesta Boston is a AAA approved Four Diamond upscale hotel offering guests spectacular city views, luxury accommodations, regional cuisine, and contemporary art.

For the traveler looking to experience the best Boston has to offer, there are many shops, museums, and historical sites conveniently located near the Royal Sonesta Boston, known as one of the best Boston luxury hotels. The hotel also offers weekday SUV service to the Cambridge area.

Hotel name Royal Sonesta 40 Edwin Land BoulevardCambridge, MA 02142 USA

Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

crispr-congress.com/register Tel: +1 212 531 5898 Email: [email protected]

Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

• 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

TEAM DISCOUNTS*

Health & Medicine

CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA